CDKL5 and craniodiaphyseal dysplasia: We used our existing CDD model which utilised a patient-derived male iPSC line [CDKL5; c.175C > T, p.(Arg59*)] and CRISPR-Cas9 gene-corrected isogenic controls (genetically matched) [28].